SCHEMBL474059

SCHEMBL474059

Cn1c(=O)oc2cc(C(=O)Cc3ccc(Br)cc3Cl)ccc21

nearest known ligand 0.49

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.49
HPGD P15428 1/20 0.49
CBX7 O95931 2/20 0.44
CDYL Q9Y232 2/20 0.44
CDY1; CDY1B Q9Y6F8 2/20 0.44
KDM4E B2RXH2 1/20 0.44
KMT2A Q03164 4/20 0.41
MEN1 O00255 3/20 0.40
MAPT P10636 3/20 0.40
TP53 P04637 2/20 0.40
POLB P06746 1/20 0.40
TDP1 Q9NUW8 1/20 0.40
CDYL2 Q8N8U2 1/20 0.40
SIGMAR1 Q99720 1/20 0.40
NPC1 O15118 1/20 0.39
TSHR P16473 2/20 0.39
LMNA P02545 1/20 0.38
PKM P14618 2/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL473912 0.91 CBX7 (0.44) ALDH1A1HPGDCBX7CDYLCDY1; CDY1B
SCHEMBL474030 0.78 ALDH1A1 (0.49) ALDH1A1HPGDCBX7CDYLCDY1; CDY1B
SCHEMBL8948117 0.77 ALDH1A1 (0.62) ALDH1A1HPGDCBX7CDYLCDY1; CDY1B
SCHEMBL473921 0.76 CDYL2 (0.49) ALDH1A1CBX7CDYLCDY1; CDY1BKMT2A
SCHEMBL473997 0.75 CBX7 (0.42) ALDH1A1HPGDCBX7CDYLCDY1; CDY1B
SCHEMBL10392904 0.75 ALDH1A1 (0.63) ALDH1A1HPGDKDM4EKMT2AMEN1
SCHEMBL750636 0.75 ALDH1A1 (0.53) ALDH1A1HPGDKDM4EKMT2AMEN1
SCHEMBL8541265 0.74 ALDH1A1 (0.59) ALDH1A1HPGDKDM4EKMT2AMEN1
SCHEMBL10393870 0.74 ALDH1A1 (0.59) ALDH1A1HPGDKDM4EKMT2AMEN1
SCHEMBL480934 0.74 EPHX2 (0.38) ALDH1A1KDM4EPKM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2411365-B1 2,3-DIARYL- OR HETEROARYL-SUBSTITUTED 1,1,1-TRIFLUORO-2-HYDROXYPROPYL COMPOUNDS HOFFMANN LA ROCHE (CH) 2014-03-19 EP disclosed
US-20130172335-A1 2,3-DIARYL- OR HETEROARYL-SUBSTITUTED 1,1,1-TRIFLUORO-2-HYDROXYPROPYL COMPOUNDS HOFFMANN-LA ROCHE INC. (US) 2013-07-04 US disclosed
US-8450313-B2 2,3-diaryl- or heteroaryl-substituted 1,1,1-trifluoro-2-hydroxypropyl compounds HOFFMANN-LA ROCHE INC. (US) 2013-05-28 US disclosed
US-8268820-B2 2,3-diaryl- or heteroaryl-substituted 1,1,1-trifluoro-2-hydroxypropyl compounds HOFFMANN-LA ROCHE INC. (US) 2012-09-18 US disclosed
US-20120232071-A1 2,3-DIARYL- OR HETEROARYL-SUBSTITUTED 1,1,1-TRIFLUORO-2-HYDROXYPROPYL COMPOUNDS HUNZIKER DANIEL (CH) 2012-09-13 US disclosed
EP-2411365-A1 2,3-DIARYL- OR HETEROARYL-SUBSTITUTED 1,1,1-TRIFLUORO-2-HYDROXYPROPYL COMPOUNDS F. Hoffmann-La Roche AG (CH) 2012-02-01 EP disclosed
WO-2010108903-A1 2,3-DIARYL- OR HETEROARYL-SUBSTITUTED 1,1,1-TRIFLUORO-2-HYDROXYPROPYL COMPOUNDS F. HOFFMANN-LA ROCHE AG (CH) 2010-09-30 WO disclosed
US-20100249124-A1 2,3-DIARYL- OR HETEROARYL-SUBSTITUTED 1,1,1-TRIFLUORO-2-HYDROXYPROPYL COMPOUNDS HOFFMANN-LA ROCHE, INC. 2010-09-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130172335-A1 2,3-DIARYL- OR HETEROARYL-SUBSTITUTED 1,1,1-TRIFLUORO-2-HYDROXYPROPYL COMPOUNDS NR3C1, NR3C2, MC2R ALDH1A1 708/4885HPGD 2135/4885CBX7 3350/4885
US-20100249124-A1 2,3-DIARYL- OR HETEROARYL-SUBSTITUTED 1,1,1-TRIFLUORO-2-HYDROXYPROPYL COMPOUNDS NR3C1, NR3C2, MC2R ALDH1A1 725/4885HPGD 2335/4885CBX7 3212/4885
US-20120232071-A1 2,3-DIARYL- OR HETEROARYL-SUBSTITUTED 1,1,1-TRIFLUORO-2-HYDROXYPROPYL COMPOUNDS NR3C1, NR3C2, MC2R ALDH1A1 708/4885HPGD 2135/4885CBX7 3350/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.